<DOC>
	<DOCNO>NCT02182284</DOCNO>
	<brief_summary>The objective study establish relative bioavailability new soft gelatin capsule ( SGC ) formulation BI 201335 NA compare current solution formulation ( powder bottle , PIB ) two dos ( 40 mg , 240 mg ) parallel , two-way cross-over study design .</brief_summary>
	<brief_title>Bioavailability Soft Gelatin Capsule Formulation BI 201335 NA Compared Solution Formulation Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead ECG ( electrocardiogram ) , clinical laboratory test Age ≥18 Age ≤50 year Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance , assess investigator Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Concomitant drug opinion investigator ( consultation BI medical monitor pharmacokinetics ) , would interfere adsorption , distribution metabolism BI 201335 Use drug might reasonably influence result trial prolong QT/QTc ( correct QT interval ) interval within 30 day prior screen trial completion Use investigational drug within 30 day prior enrolment ; plan usage investigational drug course current study Smoking ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability abstain alcohol Day 14 day 22 Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance screening , accord judgement investigator A mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) Infected hepatitis A , hepatitis B hepatitis C virus ( define either hepatitis A antibody positive , hepatitis B surface antigen HBV DNA positive , hepatitis C antibody positive ) Positive ELISA HIV1 ( Human immunodeficiency virus ) HIV2 For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception , e.g . sterilisation , IUD ( intrauterine device ) , use barrier method contraception least 3 month prior participation study Are willing unable use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 2 month completion/termination trial Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>